GWLL Quote, Financials, Valuation and Earnings

Dollar Tree, Inc. has a net margin of -32% compared to Goldenwell Biotech, Inc.'s net margin of 5.15%. Goldenwell Biotech, Inc.'s return on equity of -176.34% beat Dollar Tree, Inc.'s return on equity of 24.66%.

Goldenwell Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Dollar Tree, Inc. has an analysts' consensus of $118.61 which suggests that it could fall by -9.84%. Given that Dollar Tree, Inc. has higher upside potential than Goldenwell Biotech, Inc., analysts believe Dollar Tree, Inc. is more attractive than Goldenwell Biotech, Inc..

Goldenwell Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dollar Tree, Inc. has a beta of 0.745, suggesting its less volatile than the S&P 500 by 25.533%.

Goldenwell Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dollar Tree, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Goldenwell Biotech, Inc. pays -- of its earnings as a dividend. Dollar Tree, Inc. pays out -- of its earnings as a dividend.

Goldenwell Biotech, Inc. quarterly revenues are $25K, which are smaller than Dollar Tree, Inc. quarterly revenues of $4.8B. Goldenwell Biotech, Inc.'s net income of -$8K is lower than Dollar Tree, Inc.'s net income of $244.6M. Notably, Goldenwell Biotech, Inc.'s price-to-earnings ratio is 623.05x while Dollar Tree, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldenwell Biotech, Inc. is 4,348.96x versus 1.46x for Dollar Tree, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ollie's Bargain Outlet Holdings, Inc. has a net margin of -32% compared to Goldenwell Biotech, Inc.'s net margin of 7.53%. Goldenwell Biotech, Inc.'s return on equity of -176.34% beat Ollie's Bargain Outlet Holdings, Inc.'s return on equity of 12.91%.

Goldenwell Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Ollie's Bargain Outlet Holdings, Inc. has an analysts' consensus of $141.53 which suggests that it could grow by 25.14%. Given that Ollie's Bargain Outlet Holdings, Inc. has higher upside potential than Goldenwell Biotech, Inc., analysts believe Ollie's Bargain Outlet Holdings, Inc. is more attractive than Goldenwell Biotech, Inc..

Goldenwell Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ollie's Bargain Outlet Holdings, Inc. has a beta of 0.478, suggesting its less volatile than the S&P 500 by 52.245%.

Goldenwell Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ollie's Bargain Outlet Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Goldenwell Biotech, Inc. pays -- of its earnings as a dividend. Ollie's Bargain Outlet Holdings, Inc. pays out -- of its earnings as a dividend.

Goldenwell Biotech, Inc. quarterly revenues are $25K, which are smaller than Ollie's Bargain Outlet Holdings, Inc. quarterly revenues of $613.6M. Goldenwell Biotech, Inc.'s net income of -$8K is lower than Ollie's Bargain Outlet Holdings, Inc.'s net income of $46.2M. Notably, Goldenwell Biotech, Inc.'s price-to-earnings ratio is 623.05x while Ollie's Bargain Outlet Holdings, Inc.'s PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldenwell Biotech, Inc. is 4,348.96x versus 2.76x for Ollie's Bargain Outlet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PriceSmart, Inc. has a net margin of -32% compared to Goldenwell Biotech, Inc.'s net margin of 2.31%. Goldenwell Biotech, Inc.'s return on equity of -176.34% beat PriceSmart, Inc.'s return on equity of 12.25%.

Goldenwell Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PriceSmart, Inc. has an analysts' consensus of $120.00 which suggests that it could fall by -5.97%. Given that PriceSmart, Inc. has higher upside potential than Goldenwell Biotech, Inc., analysts believe PriceSmart, Inc. is more attractive than Goldenwell Biotech, Inc..

Goldenwell Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PriceSmart, Inc. has a beta of 0.740, suggesting its less volatile than the S&P 500 by 25.996%.

Goldenwell Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PriceSmart, Inc. offers a yield of 0.99% to investors and pays a quarterly dividend of $0.63 per share. Goldenwell Biotech, Inc. pays -- of its earnings as a dividend. PriceSmart, Inc. pays out 26.14% of its earnings as a dividend. PriceSmart, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Goldenwell Biotech, Inc. quarterly revenues are $25K, which are smaller than PriceSmart, Inc. quarterly revenues of $1.3B. Goldenwell Biotech, Inc.'s net income of -$8K is lower than PriceSmart, Inc.'s net income of $30.7M. Notably, Goldenwell Biotech, Inc.'s price-to-earnings ratio is 623.05x while PriceSmart, Inc.'s PE ratio is 26.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldenwell Biotech, Inc. is 4,348.96x versus 0.73x for PriceSmart, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Target Corp. has a net margin of -32% compared to Goldenwell Biotech, Inc.'s net margin of 2.73%. Goldenwell Biotech, Inc.'s return on equity of -176.34% beat Target Corp.'s return on equity of 25.08%.

Goldenwell Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Target Corp. has an analysts' consensus of $97.21 which suggests that it could fall by -6.23%. Given that Target Corp. has higher upside potential than Goldenwell Biotech, Inc., analysts believe Target Corp. is more attractive than Goldenwell Biotech, Inc..

Goldenwell Biotech, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Target Corp. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.338%.

Goldenwell Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Target Corp. offers a yield of 4.36% to investors and pays a quarterly dividend of $1.14 per share. Goldenwell Biotech, Inc. pays -- of its earnings as a dividend. Target Corp. pays out 50.35% of its earnings as a dividend. Target Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Goldenwell Biotech, Inc. quarterly revenues are $25K, which are smaller than Target Corp. quarterly revenues of $25.3B. Goldenwell Biotech, Inc.'s net income of -$8K is lower than Target Corp.'s net income of $689M. Notably, Goldenwell Biotech, Inc.'s price-to-earnings ratio is 623.05x while Target Corp.'s PE ratio is 12.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Goldenwell Biotech, Inc. is 4,348.96x versus 0.45x for Target Corp.. Usually stocks with elevated PS ratios are considered overvalued.